Method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)
A method for treating or preventing idiopathic polypoidal choroidal vasculopathy is provided comprising intravitreal injections of Zimura™ (or another anti-C5 agent) and Eylea® (or another VEGF antagonist).
1. A method for treating idiopathic polypoidal choroidal vasculopathy (IPCV), comprising administering to a subject in need thereof:
(a) an anti-C5 agent and (b) a VEGF antagonist,
wherein (a) and (b) are administered in an amount that is effective for treating IPCV,
wherein the administering occurs for a first administration period induction phase followed by a second administration period maintenance phase wherein only the anti-C5 agent is administered monthly throughout the maintenance phase, and
wherein the anti-C5 agent is a pegylated aptamer (avacincaptad pegol) with the following nucleotide sequence:
fCmGfCfCGfCmGmGfUfCfUfCmAmGmGfCGfCfUmGmAmGfUfCfUmG mAmGfUfUfUAfCf CfUmGfCmG-3T (SEQ ID NO: 1), or a pharmaceutically acceptable salt thereof,
wherein fC and fU=2′-fluoro nucleotides, and mG and mA=2′-OMe nucleotides and all other nucleotides are 2′-OH, and where 3T indicates an inverted deoxythymidine.
2. The method of claim 1 wherein the administering occurs once every month, ± about seven days, for a first administration period of at least three consecutive months, said first administration period comprises administration of (a) and (b) on the same day followed by administration of a subsequent dose of (a) after about 14 days.
3. The method of claim 2 wherein (a) and (b) are administered for a second administration period after completion of said first administration period, wherein (a) is administered at least once every month during said second administration period and (b) is administered once every other month together with administration of (a) during said second administration period.
4. The method of claim 3 wherein an additional dose of (a) is administered during said second administration period during months when (a) and (b) are both administered.
5. The method of claim 4 wherein said additional dose of (a) is administered about 48 hours before administering (a) and (b) on the same day.
6. The method of claim 3 wherein (a) and (b) are administered on the same day during the second administration period.
7. The method of claim 3 wherein avacincaptad pegol is administered intravitreally in an amount of 4.0 mg/eye once every month when (b) is not administered.
8. The method of claim 3 wherein the avacincaptad pegol or pharmaceutically acceptable salt thereof is administered intravitreally and in an amount of about 2.0 mg/eye.
9. The method of claim 8 wherein the VEGF antagonist is ranibizumab, bevacizumab, pegaptanib sodium, tivozanib, ESBA1008 or aflibercept.
10. The method of claim 9 wherein the VEGF antagonist is administered intravitreally.
11. The method of claim 10 wherein the VEGF antagonist is aflibercept and is administered in an amount of about 2 mg/eye, bevacizumab and is administered in an amount of about 1.25 mg/eye, or ranibizumab and is administered in an amount of about 0.5 mg/eye.
12. The method of claim 11 wherein the VEGF antagonist is aflibercept and is administered in an amount of about 2 mg/eye.
13. The method of claim 12 wherein avacincaptad pegol is administered intravitreally in an amount of 4.0 mg/eye once every month when (b) is not administered.
14. The method of claim 12 wherein avacincaptad pegol is administered after aflibercept during said first administration period.
15. The method of claim 14 wherein an additional dose of avacincaptad pegol is administered during said second administration period on months when avacincaptad pegol and aflibercept are both administered.
16. The method of claim 1 wherein (a) is administered after (b) during said first administration period.
17. The method of claim 1 wherein the avacincaptad pegol or pharmaceutically acceptable salt thereof is administered intravitreally and in an amount of about 2.0 mg/eye.
18. A method for treating idiopathic polypoidal choroidal vasculopathy (IPCV), comprising administering to a subject in need thereof: (a) an anti-C5 agent and (b) a VEGF antagonist, wherein (a) and (b) are administered in an amount that is effective for treating IPCV, and wherein the administering occurs for a first administration period induction phase followed by a second administration period maintenance phase wherein only the anti-C5 agent is administered monthly throughout the maintenance phase, wherein the anti-C5 agent is selected from the group consisting of eculizumab, LFG-316, and A217.